BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 25581732)

  • 21. Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the "sectioning and extensively examining the FIMbriated end" (SEE-FIM) protocol?
    Mahe E; Tang S; Deb P; Sur M; Lytwyn A; Daya D
    Int J Gynecol Pathol; 2013 Jul; 32(4):353-7. PubMed ID: 23722507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin?
    Gao FF; Bhargava R; Yang H; Li Z; Zhao C
    Hum Pathol; 2013 Aug; 44(8):1534-43. PubMed ID: 23465279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
    D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
    Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphologic and Molecular Heterogeneity of High-grade Serous Carcinoma Precursor Lesions.
    Chien YW; Wang Y; Huang P; Lawson BC; Kolin DL; Chui MH; Vang R; Numan TA; Soong TR; Wang BG; Smith SA; Chen CL; Stone R; Douville C; Wang TL; Shih IM
    Am J Surg Pathol; 2024 Apr; 48(4):475-486. PubMed ID: 38298022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer.
    Asaka S; Davis C; Lin SF; Wang TL; Heaphy CM; Shih IM
    Am J Surg Pathol; 2019 Aug; 43(8):1083-1091. PubMed ID: 31107721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report.
    Suda K; Nakaoka H; Hata C; Yahata N; Isobe M; Kameyama H; Wakai T; Motoyama T; Inoue I; Yoshihara K; Enomoto T
    Diagn Pathol; 2019 Feb; 14(1):17. PubMed ID: 30744657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
    Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
    Stanciu PI; Ind TEJ; Barton DPJ; Butler JB; Vroobel KM; Attygalle AD; Nobbenhuis MAE
    J Ovarian Res; 2019 May; 12(1):50. PubMed ID: 31128592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
    Bijron JG; Seldenrijk CA; Zweemer RP; Lange JG; Verheijen RH; van Diest PJ
    Am J Surg Pathol; 2013 Aug; 37(8):1123-30. PubMed ID: 23648462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.
    Schmoeckel E; Odai-Afotey AA; Schleißheimer M; Rottmann M; Flesken-Nikitin A; Ellenson LH; Kirchner T; Mayr D; Nikitin AY
    Mod Pathol; 2017 Sep; 30(9):1241-1250. PubMed ID: 28664938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of Preinvasive Lesions.
    Patrono MG; Corzo C; Iniesta M; Ramirez PT
    Clin Obstet Gynecol; 2017 Dec; 60(4):771-779. PubMed ID: 28957950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
    Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
    Zhai Y; Wu R; Kuick R; Sessine MS; Schulman S; Green M; Fearon ER; Cho KR
    J Pathol; 2017 Sep; 243(1):16-25. PubMed ID: 28608929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fallopian tube: the dark face of pelvic carcinogenesis].
    Watkin E; Devouassoux-Shisheboran M
    Ann Pathol; 2011 Oct; 31(5):345-52. PubMed ID: 21982240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia.
    Rabban JT; Vohra P; Zaloudek CJ
    Am J Surg Pathol; 2015 Jan; 39(1):35-51. PubMed ID: 25025442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
    Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.